Thannickal, T.C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469–474 (2000).
Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991–997 (2000).
Mignot, E. et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. 68, 686–699 (2001).
Hallmayer, J. et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat. Genet. 41, 708–711 (2009).
Cvetkovic-Lopes, V. et al. Elevated Tribbles homolog 2–specific antibody levels in narcolepsy patients. J. Clin. Invest. 120, 713–719 (2010).
Kawashima, M. et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 33, 869–874 (2010).
Toyoda, H. et al. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 33, 875–878 (2010).
Hor, H. et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat. Genet. 42, 786–789 (2010).
Hong, S.C. et al. DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Hum. Immunol. 68, 59–68 (2007).
Amisten, S. et al. Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11. Eur. Heart J. 28, 13–18 (2007).
Matsuki, K. et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 339, 1052 (1992).
Communi, D., Suarez-Huerta, N., Dussossoy, D., Savi, P. & Boeynaems, J.M. Cotranscription and intergenic splicing of human P2Y11 and SSF1 genes. J. Biol. Chem. 276, 16561–16566 (2001).
Bours, M.J., Swennen, E.L., Di Virgilio, F., Cronstein, B.N. & Dagnelie, P.C. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358–404 (2006).
Di Virgilio, F., Boeynaems, J. & Robson, S.C. Extracellular nucleotides as negative modulators of immunity. Curr. Opin. Pharmacol. 9, 507–513 (2009).
Communi, D., Govaerts, C., Parmentier, M. & Boeynaems, J.M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J. Biol. Chem. 272, 31969–31973 (1997).
Bodin, P. & Burnstock, G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm. Res. 47, 351–354 (1998).
Chen, Y. et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314, 1792–1795 (2006).
Elliott, M.R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282–286 (2009).
Ben Yebdri, F., Kukulski, F., Tremblay, A. & Sévigny, J. Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. Eur. J. Immunol. 39, 2885–2894 (2009).
Peng, L., Bradley, C.J. & Wiley, J.S. P2Z purinoceptor, a special receptor for apoptosis induced by ATP in human leukemic lymphocytes. Chin. Med. J. 112, 356–362 (1999).
Aswad, F., Kawamura, H. & Dennert, G. High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J. Immunol. 175, 3075–3083 (2005).
Aswad, F. & Dennert, G. P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes. Cell. Immunol. 243, 58–65 (2006).
Taylor, S.R.J. et al. Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. J. Immunol. 180, 300–308 (2008).
Moore, D.J. et al. Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. Biochim. Biophys. Acta 1521, 107–119 (2001).
Vaughan, K.R. et al. Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. J. Immunol. 179, 8544–8553 (2007).
Schnurr, M. et al. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood 102, 613–620 (2003).
Ullmann, H. et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J. Med. Chem. 48, 7040–7048 (2005).
Meis, S. et al. NF546 [4,4′-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1 (4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha′-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of IL-8 from human monocyte-derived dendritic cells. J. Pharmacol. Exp. Ther. 332, 238–247 (2010).
Duhant, X. et al. Extracellular adenine nucleotides inhibit the activation of human CD4+ T lymphocytes. J. Immunol. 169, 15–21 (2002).
Gorini, S. et al. ATP secreted by endothelial cells blocks CX3CL1-elicited natural killer cell chemotaxis and cytotoxicity via P2Y11 receptor activation. Blood 116, 4492–4500 (2010).
Aran, A. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32, 979–983 (2009).
Marteau, F. et al. Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells. J. Leukoc. Biol. 76, 796–803 (2004).
Wilkin, F. et al. The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J. Immunol. 166, 7172–7177 (2001).